Collectively, our data show that CA9 knockdown suppresses proliferation via metabolic reprogramming and reduced cell migration, reaffirming that CA9 is a potential therapeutic target for ccRCC treatment. This evidence concerns the gene CA9 and nonpapillary renal cell carcinoma.